HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
→ Vertex's cystic fibrosis drugs (Trikafta, Kalydeco, etc.) are small-molecule drugs that would face negotiation sooner under current law. Delay protects those revenues.
HR1492